

EXHIBIT A: MARKED UP VERSION OF THE CLAIM

Application No.09/873,403 (Attorney Docket No. 8449-178)

(as elected under 37 C.F.R. § 1.142)

Matter that has been added is indicated by underlining and matter that has been [deleted] is indicated by bracketing.

1. (amended) A pharmaceutical composition comprising an amount of a purified molecular complex effective for treatment or prevention of an infectious disease or [cancer] a proliferative disorder, and a pharmaceutically acceptable carrier, said molecular complex comprising an alpha (2) macroglobulin polypeptide noncovalently associated with an antigenic molecule which displays the antigenicity of (i) an antigen of an infectious agent or (ii) an antigen overexpressed in a [cancer] cell of a proliferative disorder relative to its expression in a [noncancerous] cell of said cell type that is not of said proliferative disorder.

3. (amended) The pharmaceutical composition of Claim 1 wherein the proliferative disorder is cancer and wherein the antigenic molecule displays the antigenicity of an antigen overexpressed in a cancer cell relative to its expression in a noncancerous cell of said cell type.

7. (amended) A purified molecular complex comprising an alpha (2) macroglobulin polypeptide noncovalently associated with an antigenic molecule of an infectious agent or an antigen overexpressed in a [cancer] cell of a proliferative disorder cell relative to its expression in a [noncancerous] cell of said cell type that is not of said proliferative disorder.
